Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Average Rating of “Hold” from Brokerages

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have received a consensus recommendation of “Hold” from the five brokerages that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $36.25.

Several equities analysts have weighed in on the company. Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Sunday, March 29th. Canaccord Genuity Group raised their price target on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a report on Thursday, March 5th. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st.

Smith & Nephew SNATS Stock Up 1.4%

SNN opened at $32.61 on Tuesday. The company has a fifty day moving average of $34.18 and a 200 day moving average of $34.16. Smith & Nephew SNATS has a fifty-two week low of $23.91 and a fifty-two week high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS (NYSE:SNN) last posted its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share for the quarter. The company had revenue of $1.60 billion for the quarter. As a group, sell-side analysts forecast that Smith & Nephew SNATS will post 1.69 earnings per share for the current fiscal year.

Smith & Nephew SNATS Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be paid a $0.482 dividend. This represents a dividend yield of 304.0%. The ex-dividend date of this dividend is Friday, March 27th.

Hedge Funds Weigh In On Smith & Nephew SNATS

A number of institutional investors and hedge funds have recently made changes to their positions in SNN. JPMorgan Chase & Co. grew its stake in shares of Smith & Nephew SNATS by 6,663.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after buying an additional 1,192,755 shares in the last quarter. Todd Asset Management LLC purchased a new position in shares of Smith & Nephew SNATS in the 3rd quarter worth $26,319,000. Goldman Sachs Group Inc. grew its stake in shares of Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after buying an additional 583,809 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Smith & Nephew SNATS by 139.9% in the 3rd quarter. Bank of America Corp DE now owns 987,274 shares of the medical equipment provider’s stock worth $35,828,000 after purchasing an additional 575,666 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Smith & Nephew SNATS by 365.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider’s stock worth $19,742,000 after purchasing an additional 505,934 shares during the period. 25.64% of the stock is owned by hedge funds and other institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.